Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry

Journal of Invasive Cardiology

Volumn 24, Issue 10, 2012, Pages 495-502

  Damman, Peter ^a   Abdel Wahab, Mohamed ^b   Möllmann, Helge ^c   Richardt, Gert ^b   Chevalier, Bernard ^d   Barragan, Paul ^e   Tijssen, Jan G P ^a   Underwood, Paul ^f   Hamm, Christian W ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF KIEL   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

^d INSTITUT HOSPITALIER JACQUES CARTIER   (France)

^e Polyclinique les Fleurs ^*  (France)

^f BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; RAPAMYCIN; ZOTAROLIMUS;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GERMANY; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; REGISTRIES; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84867766781     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-948.
2. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare-metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
3. Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. 2010;363(24):2310-2319.
4. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56(10 Suppl):S1-S42.
5. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369(9562):667-678.
6. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998-1008.
7. Mukherjee D, Moliterno DJ. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data. JACC Cardiovasc Interv. 2009;2(12):1236-1239.
8. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48(12):2440-2447.
9. Eisenstein EL, Leon MB, Kandzari DE, et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009;2(12):1199-1207.
10. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010;375(9720):1090-1099.
11. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus-and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010;56(15):1187-1195.
12. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136-146.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
14. Windecker S. LESSON I (long-term comparison of Everolimus-eluting and Sirolimus-eluting stents for coronary revascularization). Presented at ESC conference 2010 in Stockholm, Sweden.
15. Late breaking clinical trials and first report investigations. J Am Coll Cardiol. 2010;56(13 Meeting Abstracts):xii.
16. Chevalier B. SPIRIT V single arm study: 2 year follow-up (Abstr). EuroIntervention. 2011.
17. Sarno G, Lagerqvist B, Frobert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606-613.
18. Latib A, Ferri L, Ielasi A, et al. Clinical outcomes after unrestricted implantation of everolimus-eluting stents. JACC Cardiovasc Interv. 2009;2(12):1219-1226.
19. Lotan C, Meredith IT, Mauri L, et al. Safety and effectiveness of the endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv. 2009;2(12):1227-1235.
20. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113(11):1434-1441.
21. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011;57(16):1700-1708.
22. von BC, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus Everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350-1361.